Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. May 16, 2025; 13(14): 101981
Published online May 16, 2025. doi: 10.12998/wjcc.v13.i14.101981
Published online May 16, 2025. doi: 10.12998/wjcc.v13.i14.101981
Vitiligo-like rash in a patient with lung cancer caused by sintilimab: A case report
Xiao-Ming Mao, Wei-Hua Wang, Department of Respiratory and Critical Care Medicine, Jiangshan People’s Hospital, Jiangshan 324100, Zhejiang Province, China
Author contributions: Mao XM and Wang WH wrote the original manuscript; Wang WH reviewed and edited the manuscript; All authors thoroughly reviewed and approved the final manuscript.
Informed consent statement: Written informed consent was obtained from the patient and submitted.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei-Hua Wang, Department of Respiratory and Critical Care Medicine, Jiangshan People’s hospital, No. 9 Hangbengshan Road, Jiangshan 324100, Zhejiang Province, China. mxm0077@163.com
Received: October 3, 2024
Revised: December 14, 2024
Accepted: December 27, 2024
Published online: May 16, 2025
Processing time: 103 Days and 13.2 Hours
Revised: December 14, 2024
Accepted: December 27, 2024
Published online: May 16, 2025
Processing time: 103 Days and 13.2 Hours
Core Tip
Core Tip: The article presents a case study of a 63-year-old male with non-small cell lung cancer treated effectively with chemotherapy and immunotherapy, despite developing immune-related skin adverse events manifesting as a vitiligo-like rash. Treatment with sintilimab, a programmed death 1 inhibitor, resulted in tumor regression and highlights the need for further research into the prognostic significance and mechanisms of vitiligo-like rash in patients with lung cancer undergoing immunotherapy.